Daily Updates on Generic Entry, Litigation, Biosimilars, and more …
Want insights into the biggest revenue-changing events?
Billions of dollars in sales can evaporate overnight as drug patents expire and competitors enter the market.
By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay one step ahead.
Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment
Completed
National Cancer Institute (NCI)
Phase 2
2003-06-01
RATIONALE: Cyproheptadine and megestrol may improve appetite and help prevent weight loss in
children with cancer.
PURPOSE: This phase II trial is studying how well cyproheptadine and megestrol work in
improving appetite and preventing weight loss in children with cachexia caused by cancer or
cancer treatment.
Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment
Completed
University of South Florida
Phase 2
2003-06-01
RATIONALE: Cyproheptadine and megestrol may improve appetite and help prevent weight loss in
children with cancer.
PURPOSE: This phase II trial is studying how well cyproheptadine and megestrol work in
improving appetite and preventing weight loss in children with cachexia caused by cancer or
cancer treatment.
Prazosin Treatment for Combat Trauma PTSD (Post-Traumatic Stress Disorder) Nightmares and Sleep Disturbance
Completed
VA Office of Research and Development
Phase 4
2003-10-01
The purpose of this study is to determine whether prazosin will reduce the incidence of
nightmares, sleep disturbance, and overall symptoms in combat trauma-exposed individuals
with PTSD.
Topiramate for the Prophylactic Treatment of Cyclic Vomiting Syndrome in Children
Terminated
Ortho-McNeil Neurologics, Inc.
Phase 4
2006-03-01
The purpose of this study is to assess the effectiveness, tolerability and safety of oral
topiramate for the preventative management of Cyclic Vomiting Syndrome. It is believed that
topiramate will decrease the frequency, duration and severity of attacks experienced by
children and adolescents with Cyclic Vomiting Syndrome.
Topiramate for the Prophylactic Treatment of Cyclic Vomiting Syndrome in Children
Terminated
Monarch Medical Research
Phase 4
2006-03-01
The purpose of this study is to assess the effectiveness, tolerability and safety of oral
topiramate for the preventative management of Cyclic Vomiting Syndrome. It is believed that
topiramate will decrease the frequency, duration and severity of attacks experienced by
children and adolescents with Cyclic Vomiting Syndrome.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
